Higher activity of Ezh2 has been reported in different cancers such as breast, lung, and prostate, as well as hematological malignancies, and is associated with poor disease prognosis (Kleer et al., 2003; Weikert et al., 2005; Simon and Lange, 2008; Li et al., 2013; Wang et al., 2016). This evidence concerns the gene EZH2 and cancer.